Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline Posted on May 9, 2024September 26, 2024 by KBD Admin
Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital Posted on April 30, 2024September 26, 2024 by KBD Admin
Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseases Posted on April 10, 2024September 26, 2024 by KBD Admin
Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline Posted on March 14, 2024September 26, 2024 by KBD Admin
Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis Posted on March 13, 2024September 26, 2024 by KBD Admin
Applied Therapeutics Announces $100 Million Private Placement Posted on February 28, 2024September 26, 2024 by KBD Admin
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock Posted on February 7, 2024September 26, 2024 by KBD Admin
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement Posted on February 5, 2024September 26, 2024 by Kate Schykerynec
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing Posted on February 5, 2024September 26, 2024 by Kate Schykerynec
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors Posted on January 29, 2024September 26, 2024 by KBD Admin
